The fundamental issue is that the skin barrier prevents the absorption of weight loss compounds at levels that could meaningfully affect appetite or metabolism
In the meantime, mitochondrial dysfunction is induced by hepatic IR and lipid accumulation and the lipid peroxidation mediated by cytochrome p450 2E1 boost the production of reactive oxygen and promote the degradation of mitochondria (125), which could further lead to the lack of cellular energy and metabolic intermediates accumulation, all these may lead to the secretion of pro-inflammatory cytokines, hepatocellular apoptosis and hepatic fibrogenesis, finally resulting in cirrhosis of the liver (125) ( Figure 3 )
Generally, GLP-1 agonist medications are FDA approved for adults aged 18 years and older with certain body mass indexes (BMI) (typically a BMI of 30 or above, or a BMI of 27 or above if you have a weight-related health condition such as hypertension, high cholesterol, weight-related anxiety, liver disease, sleep apnea or PCOS)
No matter what challenges you may face on a GLP-1 medication, you are not alone
This means the medication continues protecting your blood sugar and metabolic health even when weight loss has stalled
